In a recent randomized trial, lenalidomide plus low-dose dexamethasone prolonged overall survival in patients with high-risk smoldering multiple myeloma. Although the results are impressive, the generalizability is limited to a small subset of patients. Additional studies are needed to identify specific patient populations who can benefit from early intervention.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Interpretation of cytogenetic results in multiple myeloma for clinical practice
Blood Cancer Journal Open Access 30 October 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582–2590 (2007).
Kyle, R. A. & Rajkumar, S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23, 3–9 (2009).
Mateos, M.-V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013).
Rajkumar, S. V. et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27, 1738–1744 (2013).
Bladé, J., Dimopoulos, M., Rosiñol, L., Rajkumar, S. V. & Kyle, R. A. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J. Clin. Oncol. 28, 690–697 (2010).
Rajkumar, S. V., Larson, D. & Kyle, R. A. Diagnosis of smoldering multiple myeloma. N. Engl. J. Med. 365, 474–475 (2011).
Larsen, J. T. et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27, 941–946 (2012).
Kastritis, E. et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 27, 947–953 (2012).
Rajkumar, S. V., Merlini, G. & San Miguel, J. F. Redefining myeloma. Nat. Rev. Clin. Oncol. 9, 494–496 (2012).
Hillengass, J. et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J. Clin. Oncol. 28, 1606–1610 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Rajkumar, S., Kyle, R. Treatment of smoldering multiple myeloma. Nat Rev Clin Oncol 10, 554–555 (2013). https://doi.org/10.1038/nrclinonc.2013.160
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.160
This article is cited by
-
Interpretation of cytogenetic results in multiple myeloma for clinical practice
Blood Cancer Journal (2015)
-
Treatment of smoldering multiple myeloma
Nature Reviews Clinical Oncology (2013)